Nov 03, 2021 8:57 am EDT OS Therapies Receives Rare Pediatric Disease Designation (RDD) in Osteosarcoma for OST-HER2 (Listeria monocytogenes)
Oct 22, 2021 8:33 am EDT OS Therapies Announces Dosing of First Patient in a Phase IIb Trial of OST-HER2 (Listeria monocytogenes) in Recurred, Resected Osteosarcoma
Jun 23, 2021 8:44 am EDT Children's Cancer Research Fund Supports AOST-2121 PhIIb Clinical Trial in Recurred, Resected Osteosarcoma
Jan 26, 2021 8:49 am EST OS Therapies Receives Trial Approval From Children's Oncology Group for AOST2121 / OST31-164-01 An Open-Label Phase 2 Study of Maintenance Therapy With OST31-164 After Resection of Recurrent Osteosarcoma
Nov 17, 2020 8:37 am EST OS Therapies Acquires All Indications for OST-HER2 (Listeria monocytogenes) in Solid Tumors, Including Canines
Oct 15, 2020 8:56 am EDT FDA Transfers Investigational New Drug (IND) Application OST-HER2 (Listeria monocytogenes) to OS Therapies in Record Time - Phase IIb Trial in Osteosarcoma in Early 2021
Oct 09, 2020 8:49 am EDT Dr. Jutta Wanner Joins Her Next Generation ADC Technology at OS Therapies as Chief Technology Officer
Aug 26, 2020 8:00 am EDT OS Therapies to develop BlinkBio next-generation Antibody Drug Conjugate (ADC) technology; BlinkBio CEO Colin Goddard joins OS Therapies Board
Sep 18, 2019 2:46 pm EDT Dr. Robert Petit Follows His Passion to OS Therapies as Chief Medical & Scientific Advisor